CD19 CAR T cells for multiple sclerosis: Forging further into the new frontier

The efficacy of CD19 chimeric antigen receptor (CAR) T cells in B cell malignancies has generated recent interest in their application to other B cell-related pathologies, such as autoimmune diseases. Fischbach et al. 1 Fischbach F. Richter J. Pfeffer L.K. Fehse B. Berger S.C. Reinhardt S. Kuhle J. Badbaran A. Rathje K. Gagelmann N. et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. 2024; 5: 550-558.e2 Abstract Full Text Full Text PDF Google Scholar report on the use of CD19 CAR T cells in two patients with progressive multiple sclerosis, demonstrating feasibility and safety for the first time in this disease process. The efficacy of CD19 chimeric antigen receptor (CAR) T cells in B cell malignancies has generated recent interest in their application to other B cell-related pathologies, such as autoimmune diseases. Fischbach et al. 1 Fischbach F. Richter J. Pfeffer L.K. Fehse B. Berger S.C. Reinhardt S. Kuhle J. Badbaran A. Rathje K. Gagelmann N. et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. 2024; 5: 550-558.e2 Abstract Full Text Full Text PDF Google Scholar report on the use of CD19 CAR T cells in two patients with progressive multiple sclerosis, demonstrating feasibility and safety for the first time in this disease process. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosisFischbach et al.MedMarch 29, 2024In BriefMultiple sclerosis leads to smoldering inflammation in the central nervous system upheld by proliferating immune cells, including B cells; however, current therapies remain insufficient to target these immune compartments. Here, CD19-targeted CAR-T cell therapy was applied in two patients with multiple sclerosis, showing tolerable safety with promising disease-specific target-cell effects. Full-Text PDF Open Access